Chronic T-Cell Leukemia (CTCL) Overview

Save information for later
Sign Up

Learn About Chronic T-Cell Leukemia (CTCL)

View Main Condition: Leukemia

What is the definition of Chronic T-Cell Leukemia (CTCL)?
Chronic T-cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic T-cell leukemia, there is an overproduction of T lymphocytes, which are white blood cells that fight infection. Chronic T-cell leukemia has four subtypes: 1) large granular lymphocytic leukemia (LGLL), which is slow-growing; 2) T-cell prolymphocytic leukemia (T-PLL), which is aggressive, or fast-growing; 3) adult T-cell leukemia/lymphoma (ATLL); and 4) Sezary syndrome, which is a type of T-cell lymphoma that only occurs on the skin.
What are the symptoms of Chronic T-Cell Leukemia (CTCL)?
Individuals with early chronic T-cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic T-cell leukemia depend on the type and may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); rash; frequent urination and/or constipation; night sweats; weight loss; abdominal pain or fullness; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic T-Cell Leukemia (CTCL)?
Treatment for chronic T-cell leukemia depends on the type and stage. Early stage chronic T-cell leukemia may not need treatment and may involve watchful waiting. Treatments for intermediate and advanced stages chronic T-cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, splenectomy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic T-Cell Leukemia (CTCL) Local Doctors?
Elite in Chronic T-Cell Leukemia (CTCL)
Dr. Tapan M. Kadia
Hematology | Oncology
Elite in Chronic T-Cell Leukemia (CTCL)
Dr. Tapan M. Kadia
Hematology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist and an Oncologist in Houston, Texas. Dr. Kadia is rated as an Elite provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Michael J. Hallek
Elite in Chronic T-Cell Leukemia (CTCL)
Michael J. Hallek
Elite in Chronic T-Cell Leukemia (CTCL)
Michael J. Hallek
Kerpener Street 62, 
Koeln, NW, DE 

Michael Hallek practices in Koeln, Germany. Mr. Hallek is rated as an Elite expert by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Prolymphocytic Leukemia, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Stephan Stilgenbauer
Elite in Chronic T-Cell Leukemia (CTCL)
Stephan Stilgenbauer
Elite in Chronic T-Cell Leukemia (CTCL)
Stephan Stilgenbauer
Albert Einstein Allee 23, 
Ulm, BW, DE 

Stephan Stilgenbauer practices in Ulm, Germany. Mr. Stilgenbauer is rated as an Elite expert by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

View All Doctors
What are the latest Chronic T-Cell Leukemia (CTCL) Clinical Trials?
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Who is this study for: Patients with Lymphomas
Enrollment Status: Recruiting
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Ruxolitinib, Duvelisib
Study Phase: Phase 1

Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma. This study has three parts: dose escalation (Part 1), dose expansion (Part 2), and TFH/T-PLL cohort expansion (Part 3).

Match to trials
Find the right clinical trials for you in under a minute
Get started
The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens
The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens
Enrollment Status: Recruiting
Publish Date: May 21, 2025
Intervention Type: Other

Summary: The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

View All Clinical Trials